Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
March 29, 2022 09:00 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic...
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
March 21, 2022 08:00 ET
|
Turning Point Therapeutics, Inc.
Enrollment target achieved for expansion cohort 6 (EXP-6) for repotrectinib in NTRK-positive TKI-pretreated advanced solid tumors Company anticipates second repotrectinib pre-NDA meeting in first...
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
March 09, 2022 16:05 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update
March 07, 2022 17:00 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
March 01, 2022 16:05 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
February 28, 2022 16:02 ET
|
Turning Point Therapeutics, Inc.
On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation in...
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
February 02, 2022 09:00 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer
January 20, 2022 09:00 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones
January 18, 2022 09:00 ET
|
Turning Point Therapeutics, Inc.
Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated NSCLC cohort TRIDENT-1...
Turning Point Therapeutics Provides Regulatory Updates
December 20, 2021 08:00 ET
|
Turning Point Therapeutics, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...